Acute Leukemias IV pp 370-373 | Cite as
R-metHuG-CSF Combined with Chemotherapy for Treatment of Adult ALL — Pilot Study
Abstract
Chemotherapy is highly effective for treatment of acute lymphoblastic leukemia (ALL). Complete remission rates of > 75% have been achieved with most of the current protocols. Disease related and/or chemotherapy-induced granulocytopenia is the major problem during induction treatment, which may cause lifethreatening infections and will often require dose reductions of the cytostatic agents. Granulocyte colony stimulating factor (G-CSF) enhances the production of neutrophil granulocytes. It has been successfully used to ameliorate chemotherapy-induced granulocytopenia in small-cell lung cancer [1] and in induction chemotherapy in acute non-lymphoblastic leukemia (ANLL) [2]. Since G-CSF does not stimulate the growth of lymphoblasts in vitro it appeared feasible to administer G-CSF concurrently with chemotherapy during induction therapy of ALL.
Keywords
Acute Lymphoblastic Leukemia Granulocyte Colony Stimulate Factor Induction Treatment Complete Remission Rate Historical Control GroupPreview
Unable to display preview. Download preview PDF.
References
- 1.Crawford J, Ozer H, Stoller R, Johson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J (1991) Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325 (3): 164–170PubMedCrossRefGoogle Scholar
- 2.Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Akira B, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F (1990) Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323: 871–7PubMedCrossRefGoogle Scholar
- 3.Hoelzer D, Thiel E, Löffier H, Bodenstein H, Plaumann L, Büchner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R, Müller U, Wendt FC, Sodomann H, Rühl H, Herrmann F, Kaboth W, Dietzfelbinger H, Pralle H, Lunscken Ch, Hellriegel KP, Spors S, Nowrousian RM, Fischer J, Fülle H, Mitrou PS, Pfreundschuh M, Görg Ch, Emmerich B, Queisser W, Meyer P, Labedzki L, Essers U, König H, Mainzer K, Herrmann R, Messerer D, Zwingers T (1984) Intensified therapy in acute lymphoblastic and acute undi fferentiated leukemia in adults. Blood 64: 38–47PubMedGoogle Scholar
- 4.Hoelzer D, Thiel E, Löffier H, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rühl H, Maschmeyer G, Lipp T, Nowrousian M, Burkert M, Gerecke D, Pralle H, Müller U, Lunscken Ch, Fülie H, Ho AD, Küchler R, Busch FW, Schneider W, Görg Ch, Emmerich B, Braumann D, Vaupel HA, von Paleske A, Bartels H, Neiss A, Messerer D (1988) Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71: 123–131PubMedGoogle Scholar